Showing results (41-50 of 104) with videos related to

Sort By:
Pageof 11
Biorxiv : the Preprint Server for Biology|February 6, 2026
Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung CancerTakashi Sakai, Zofia Piotrowska, Charlotte I Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation DiversityIbiayi Dagogo-Jack, Marguerite Rooney, Jessica J Lin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2023
MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLCNaoki Haratake, Hiroki Ozawa, Yoshihiro Morimoto, et al.
Signal Transduction and Targeted Therapy|November 27, 2025
MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancerShinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
Suppression of PP2A-B56α Drives EMT in EGFR Mutant Non-Small Cell Lung CancerBrittany N Heil, Garima Baral, Claire M Pfeffer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2021
A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET InhibitorIbiayi Dagogo-Jack, Philicia Moonsamy, Justin F Gainor, et al.
Science Translational Medicine|August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanomaRyan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
Cancer Research Communications|August 23, 2024
Targeting TREX1 Induces Innate Immune Response in Drug-Resistant Small-Cell Lung CancerTakahiko Murayama, Navin R Mahadevan, Catherine B Meador, et al.
Science Translational Medicine|March 30, 2022
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cellsMoiez Ali, Min Lu, Hazel Xiaohui Ang, et al.
Nature Communications|August 11, 2019
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical modelsRyohei Katayama, Bo Gong, Noriko Togashi, et al.
Pageof 11